New standards in protecting high-risk patients: learnings from the ONTARGET^® programme

Monday 1st September 2008

New standards in protecting high-risk patients: learnings from the ONTARGET^® programme

Munich, Germany

The ONTARGET^® Trial Programme is the largest cardiovascular clinical investigation ever undertaken with an angiotensin II receptor blocker (ARB) and has gained a lot of attention since the initial presentation of its results on March 2008 at the American College of Cardiology (ACC) in Chicago.

The aim of the first of two Boehringer Ingelheim and Bayer Schering Pharma satellite symposia, entitled “New standards in protecting high-risk patients: learning from the ONTARGET^® programme”, was to further evaluate the ONTARGET^® trial results and their implications on daily clinical practice.

During this first satellite symposium, international experts from Canada, France, UK and Germany presented new insights from the ONTARGET^® trial providing evidence for protection of patients of high cardio and vascular risk. The symposium was chaired by Professors Faiez Zannad (France) and Salim Yusuf (Canada).

The following presentations are available as webcasts under the respective links:

Introduction

Faiez Zannad, France

The rationale for choosing telmisartan and ramipril in The ONTARGET^® Programme

Thomas Unger, Germany

Clinical evidence from ONTARGET^®: proven cardio & vascular protection

Koon Teo, Canada

Additional evidence from ONTARGET^®

Peter Sleight, UK

Cardio & vascular protection: a breakthrough for high-risk patients?

Michael Böhm, Germany

Panel discussion

All, facilitated by Peter Sleight, UK

^* Telmisartan is currently only approved for the treatment of hypertension

These webcasts follow the presentations held on occasion of the European Society of Cardiology 2008 congress between 30th August - 3rd September 2008. They are reproduced here for your personal information. Pursuant to our Terms of Use any sort of reproduction or downloading, in total or in part, is prohibited.